Joseph R. Shaw, MD MSc FRCPC is a hematologist and thrombosis medicine specialist in the Department of Medicine at The Ottawa Hospital. He is an Associate Scientist at the Ottawa Hospital Research Institute and an Assistant Professor in the Faculty of Medicine at the University of Ottawa. He completed his undergraduate studies in Biochemistry at McGill University, followed by his M.D., Internal Medicine and Hematology training at the University of Ottawa, as well as Royal College of Physicians and Surgeons AFC training in Adult Thrombosis Medicine through the Thrombosis Unit at The Ottawa Hospital. He also completed a Master of Science in Epidemiology through the University of Ottawa. His thesis dissertation was on the utility of thrombin generation assays towards measuring the anticoagulant effects of direct oral anticoagulants and anticoagulation reversal.
Dr. Shaw’s research is focused on evaluating anticoagulation reversal strategies, as well as the perioperative management of anticoagulants. He is interested in studying the potential clinical applications of thrombin generation assays, including evaluating anticoagulant pharmacodynamics and the effects of reversal agents and hemostatic therapies. He is currently the lead investigator for a prospective observational study (GAUGE) evaluating the effects of prothrombin complex concentrates on thrombin generation parameters among patients with direct Xa inhibitor-associated bleeding. Dr. Shaw holds grant funding through the PSI Foundation for the GAUGE study.
He has presented his research at national and international conferences. His research on biomarker-enhanced VTE risk stratification among patients with cancer was awarded the Canadian Hematology Society’s John H. Crookston Award in 2019 and his publication on the perioperative management of anticoagulation among patients with cancer-associated VTE was recognized with the Journal of Thrombosis and Haemostasis’ Editors Award in 2020.
1. Hrubesz G, Dwyer K, McIsaac D, Sood M, Clark E, Douketis J, Carrier M,
Shaw JR. Perioperative Management of Apixaban in Patients with Advanced CKD Undergoing a Planned Invasive Procedure.
Blood Adv. 2024 Feb 13;8(3):732-735.
2.Shaw JR,
James T, Douxfils J, Dargaud Y, Levy JH, Brinkman HJM, Shorr R, Siegal D,
Castellucci LA, Gross P, Khalife R, Sperling C, Page D, Fergusson D, Carrier M.
(2023) Thrombin generation, bleeding and hemostasis in humans: Protocol for a
scoping review of the literature.
PLoS One. 2023 Nov 1;18(11)
3. Shaw JR, Li N, Abdulrehman J, Stella SF, St John M, Nixon J,
Spyropoulos AC, Schulman S, Wang TF, Carrier M, Douketis JD. (2023)
Periprocedural Management of Direct Oral Anticoagulants in Patients with Atrial
Fibrillation and Active Cancer.
J Thromb Haemost. 2023 Nov
8:S1538-7836(23)00830-9. doi: 10.1016/j.jtha.2023.10.028. Epub ahead of print.
PMID: 37949316
4. Shaw
JR, Unachukwu U, Cyr J,
Siegal DM, Castellucci LA, Dreden PV, Dowlatshahi D, Buyukdere H, Ramsay T,
Carrier M. (2023) Effect of PCC on Thrombin Generation among Patients on Factor
Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and
Rationale.
TH Open. 2023 Jul 25;7(3):e229-e240.
5.Lun
R.,
Shaw JR., Roy DC., Siegal D., Ramsay T., Chen Y., Dowlatshahi D. (2023).
Effect modification of age and hypertension on cancer and prevalence of
self-reported stroke – A cross-sectional study.
Cancer Med; 2023 Apr 21
6.Shaw JR., Castellucci LA., Siegal D., Carrier M. DOAC-associated bleeding, hemostatic strategies and thrombin generation assays - a review of the literature.
J Thromb Haemost. 2023 Mar;21(3):433-452
7. Aziz J., Wang TF., Siegal D., Douketis J., Le Gal G., Carrier M.,
Shaw JR. Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer.
J Thromb Haemost. 2023 Apr;21(4):933-943.
8. Shaw JR., Li N., Nixon J., Moffat KA., Spyropoulos AC., Schulman S., Douketis JD. Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure.
J Thromb Haemost. 2022 Dec;20(12):2953-2963
9.Shaw JR., Kumar V., Mallick R., Carrier M., Ilich A., Key N., Wells P. (2020) Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer.
Thromb Res; 196: 437-443
10.Shaw JR., Li N., Vanassche T., Coppens M., Spyropoulos A.C., Syed S., Radwi M., Duncan J., Schulman S., Douketis J. (2020) Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure.
Blood Advances; 4(15): 3520-3527
11. Shaw JR., Kaplovitch E., Douketis J. (2020) Periprocedural management of oral anticoagulation.
Med Clin North Am; 104(4): 709-726
12. Shaw JR., Siegal D.M. (2020). Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact?
Res Pract Thromb Haemost; 4(5): 677-679
13. Shaw JR., Douketis J., Le Gal G., Carrier M (2019). Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes.
J Thromb Haemost; 17(7): 1171-1178
14. Shaw JR., Siegal D.M. (2018). Pharmacological reversal of the direct oral anticoagulants – A comprehensive review of the literature.
Res Pract Thromb Haemost; 2:251-265
